Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Inclisiran for primary hypercholesterolaemia and mixed dyslipidaemia	Inclisiran (ALN-PCSsc; ALN-60212)	Heterozygous familial hypercholesterolaemia (HeFH) , Primary hypercholesterolaemia	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2019	View \| Download
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Ixazomib citrate for newly diagnosed multiple myeloma inelgible for autologous stem cell transplant– maintenance therapy	Ixazomib (Ninlaro; MLN 9708; MLN 2238; ixazomib citrate)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Lacosamide for primary generalised tonic-clonic seizures – adjunctive therapy	Lacosamide (Vimpat)	Epilepsy	Neurology	2019	View \| Download
Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma	Lenalidomide (Revlimid) , R-CHOP	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2019	View \| Download
Liraglutide for weight management in obese adolescents aged 12-17 years old	Liraglutide (Victoza; NN-2211; NN-2211 Pen Injector)	Weight management	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download
Lumacafor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 to 23 months	Orkambi (fixed dose combination: Lumacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Lumasiran for primary hyperoxaluria type 1 in paediatric patients aged up to 5 years	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
Lumasiran for primary hyperoxaluria type I	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
LY-900014 (ultra-rapid lispro) for adults with type 1 diabetes mellitus	Insulin lispro (LY-900014)	Type 1 diabetes	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download